It is desired to provide polymer compositions for use in different applications or end-user products wherein the peroxide contents are not increased even upon storing for long periods of time, thereby providing end-user products with better stability and desired performance.

SUMMARY OF THE INVENTION

[0011] One aspect of the present disclosure provides a peroxide stable polymer composition comprising: a mixture of (i) 95 *wt.%* to about 99.999 *wt. %* of polyvinylpyrrolidone/vinyl acetate copolymer (PVP/VA); and (ii) 0.001 *wt. %* to 5.0 *wt. %* of butylated hydroxy anisole (BHA).

[0012] In another aspect, the present disclosure provides a pharmaceutical composition comprising a peroxide stable polymer composition comprising a mixture of 95 *wt. %* to about 99.999 *wt. %* of polyvinylpyrrolidone/vinyl acetate copolymer (PVP/VA), and 0.001 *wt. %* to 5 *wt. %* of butylated hydroxy anisole (BHA); and at least one pharmaceutical active ingredient.

[0013] In yet another aspect, the present disclosure provides a process for preparing a peroxide stable polymer composition comprising the steps of: (i) preparing a feed mixture comprising 95 *wt. %* to about 99.999 *wt. %* of PVP/VA copolymer and 0.001 *wt. %* to 5 *wt. %* of BHA in an aqueous and/or organic solvent; and (ii) spray drying the feed mixture of process step (i) to form a free-flowing peroxide stable polymer composition comprising a mixture of PVP/VA copolymer and BHA.

[0014] Another aspect of the present disclosure provides a peroxide stable polymer composition consisting of: a mixture of (i) 95 *wt. %* to about 99.999 *wt. %* of polyvinylpyrrolidone/vinyl acetate copolymer (PVP/VA); and (ii) 0.001 *wt. %* to 5 *wt. %* of butylated hydroxy anisole (BHA).